Tags Archive Navigation
icon
-
Media ReleaseNovartis hat im zweiten Quartal dank der Dynamik wichtiger Wachstums-marken eine starke Performance erzielt; Prognose für 2021 unverändert
-
Media ReleaseNovartis: forte performance au deuxième trimestre, soutenue par la dynamique des marques clés de croissance; prévisions pour l’exercice 2021 inchangées
-
Media ReleaseNovartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.
-
Media ReleaseNovartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum
-
Media ReleaseNovartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
-
Media ReleaseNovartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)
-
Media ReleaseNovartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)
-
Media ReleaseEuropean Medicines Agency (EMA) approves safety label update for Novartis Beovu®
-
Media ReleaseNovartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
-
Media ReleaseNovartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
-
Media ReleaseNovartis data show multiple sclerosis patients and nurses prefer Kesimpta® (ofatumumab) Sensoready® autoinjector pen
-
Media ReleaseNovartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 16
- › Next page